Fig. 4From: Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)Blood pressure (BP) control rates. a BP control rates at month 3, 6, 9, and 12 after olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) administration in overall patients. b BP control rates at month 3, 6, 9, and 12 in patients treated only with OM/AML/HCTZ. Target BP, SBP/DBP < 140/90 mmHg). Effectiveness set (n = 3052). BP, blood pressure; SBP, systolic BP; DBP, diastolic BP. *P < 0.0001 (McNemar’s test)Back to article page